No

Sclerosing Agent

Mild sclerosing agent used for bleeding esophageal varices

C

Hypersensitivity to agent or oleic acid

Fatal anaphylactic shock has been reported following administration; use with caution and decrease doses in patients with significant liver dysfunction (child class C), with concomitant cardiorespiratory disease, or in the elderly or critically ill

1% to 10%:

Central nervous system: Pyrexia (1.8%)

Gastrointestinal: Esophageal ulcer (2%), esophageal stricture (1.3%)

Respiratory: Pleural effusion (2%), pneumonia (1.2%)

Miscellaneous: Retrosternal pain (1.6%)

<1%: Esophagitis, perforation, injection necrosis, acute renal failure, anaphylaxis

Anaphylaxis after administration of larger than normal volumes, severe intramural necrosis

Treatment is supportive with epinephrine, corticosteroids, fluids, and pressors

No data reported

Derived from oleic acid and similar in physical properties to sodium morrhuate; however, the exact mechanism of the hemostatic effect used in endoscopic injection sclerotherapy is not known. Intravenously injected ethanolamine oleate produces a sterile inflammatory response resulting in fibrosis and occlusion of the vein; a dose-related extravascular inflammatory reaction occurs when the drug diffuses through the venous wall. Autopsy results indicate that variceal obliteration occurs secondary to mural necrosis and fibrosis. Thrombosis appears to be a transient reaction.

Adults: 1.5-5 mL per varix, up to 20 mL total or 0.4 mL/kg for a 50 kg patient; doses should be decreased in patients with severe hepatic dysfunction and should receive less than recommended maximum dose

No information available to require special precautions

No effects or complications reported

Have epinephrine and resuscitative equipment nearby

Injection: 5% [50 mg/mL] (2 mL)